Can-Fite BioPharma (NYSEMKT:CANF) will conduct a conference call with investors to review the results of its Phase II exploratory NAFLD/NASH study with Namodenoson which achieved its primary and secondary efficacy endpoints, while showing continued safety.
Shares closed down 7%.
https://seekingalpha.com/news/3560462-can-fite-to-hold-investor-call-on-april-16-shares-down-5-premarket
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.